Despite the substantial downregulation of Bcl-2, prostate cancer cells may successfully develop drug resistance through other mechanisms, such as growth pathway stimulation or adaptation of the tumor microenvironment [37]. The gene discussed is BCL2; the disease is prostate carcinoma.